PL3345904T3 - Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych - Google Patents

Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych

Info

Publication number: PL3345904T3
Authority: PL; Poland
Prior art keywords: compounds; agonist activity; beta2 adrenergic; receptor antagonist; receptor agonist
Prior art date: 2012-12-06

Application number

PL18156043T

Other languages

English (en)

Inventor

Fabio Rancati

Ian Linney

Original Assignee

Chiesi Farmaceutici S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-06

Filing date

2013-12-05

Publication date

2020-12-14

2013-12-05 Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.

2020-12-14 Publication of PL3345904T3 publication Critical patent/PL3345904T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Pulmonology (AREA)
Organic Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Dispersion Chemistry (AREA)
Biophysics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)

PL18156043T 2012-12-06 2013-12-05 Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych PL3345904T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP12195891		2012-12-06
PCT/EP2013/075661 WO2014086924A1 (en)	2012-12-06	2013-12-05	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP18156043.4A EP3345904B1 (en)	2012-12-06	2013-12-05	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP13811827.8A EP2928889B1 (en)	2012-12-06	2013-12-05	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity

Publications (1)

Publication Number	Publication Date
PL3345904T3 true PL3345904T3 (pl)	2020-12-14

Family

ID=47323975

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL13811827T PL2928889T3 (pl)	2012-12-06	2013-12-05	Związki wykazujące aktywność antagonisty receptorów muskarynowych i aktywność agonisty receptorów beta-2 adrenergicznych
PL18156043T PL3345904T3 (pl)	2012-12-06	2013-12-05	Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL13811827T PL2928889T3 (pl)	2012-12-06	2013-12-05	Związki wykazujące aktywność antagonisty receptorów muskarynowych i aktywność agonisty receptorów beta-2 adrenergicznych

Country Status (37)

Country	Link
US (2)	US8987299B2 (pl)
EP (2)	EP3345904B1 (pl)
JP (1)	JP6421989B2 (pl)
KR (2)	KR102156443B1 (pl)
CN (1)	CN104822678B (pl)
AR (1)	AR093825A1 (pl)
AU (1)	AU2013354043C1 (pl)
BR (1)	BR112015012730B1 (pl)
CA (1)	CA2893626C (pl)
CL (1)	CL2015001483A1 (pl)
CO (1)	CO7400870A2 (pl)
CY (2)	CY1120159T1 (pl)
DK (2)	DK2928889T3 (pl)
EA (1)	EA030552B1 (pl)
ES (2)	ES2670686T3 (pl)
GE (1)	GEP20186839B (pl)
HR (2)	HRP20180915T1 (pl)
HU (2)	HUE051394T2 (pl)
IL (1)	IL239182B (pl)
LT (2)	LT3345904T (pl)
MA (1)	MA38147B1 (pl)
MX (1)	MX369311B (pl)
NZ (1)	NZ708738A (pl)
PE (1)	PE20151216A1 (pl)
PH (1)	PH12015501247B1 (pl)
PL (2)	PL2928889T3 (pl)
PT (2)	PT3345904T (pl)
RS (2)	RS60864B1 (pl)
SA (1)	SA515360514B1 (pl)
SG (2)	SG11201504318UA (pl)
SI (2)	SI3345904T1 (pl)
TN (1)	TN2015000244A1 (pl)
TR (1)	TR201808698T4 (pl)
TW (1)	TWI637954B (pl)
UA (1)	UA118181C2 (pl)
WO (1)	WO2014086924A1 (pl)
ZA (1)	ZA201503965B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITRM20110083U1 (it)	2010-05-13	2011-11-14	De La Cruz Jose Antonio Freire	Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en)	2010-05-13	2011-11-16	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592078A1 (en)	2011-11-11	2013-05-15	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
RU2661877C2 (ru) *	2012-12-06	2018-07-20	КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.	Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов
MX369311B (es) *	2012-12-06	2019-11-05	Chiesi Farm Spa	Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico.
EP2934594B1 (en)	2012-12-18	2019-09-04	Almirall, S.A.	Cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities .
TWI643853B (zh)	2013-02-27	2018-12-11	阿爾米雷爾有限公司	同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh)	2013-07-25	2018-11-21	阿爾米雷爾有限公司	具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh)	2013-07-25	2015-05-16	Almirall Sa	含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh)	2014-09-26	2016-05-16	阿爾米雷爾有限公司	具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh)	2015-02-12	2020-09-01	義大利商吉斯藥品公司	具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
AR104828A1 (es) *	2015-06-01	2017-08-16	Chiesi Farm Spa	COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
SI3377108T1 (sl) *	2015-11-16	2020-05-29	Chiesi Farmaceutici S.P.A.	Postopek za pripravo suhe praškaste formulacije, ki obsega antiholinergik, kortikosteroid in beta-adrenergik
EP3383867B1 (en)	2015-12-03	2021-04-14	Chiesi Farmaceutici S.p.A.	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2018011090A1 (en)	2016-07-13	2018-01-18	Chiesi Farmaceutici S.P.A.	Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CA2994290C (en)	2017-11-06	2024-01-23	Entech Solution As	Method and stimulation sleeve for well completion in a subterranean wellbore
EP4365162A3 (en) *	2020-12-21	2024-10-09	Intervet International B.V.	A process for the preparation of n-(bis(4-methoxyphenyl)methyl)-6-oxo-2-(pyridazin-3-yl)-1,6-dihydropyrimidine-5-carboxamide

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2222128A (en)	1937-01-29	1940-11-19	Pure Oil Co	Preparation and separation of aromatic hydrocarbons
DE19921693A1 (de)	1999-05-12	2000-11-16	Boehringer Ingelheim Pharma	Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
BR0315234A (pt)	2002-10-11	2005-08-23	Pfizer	Derivados de indol como agonistas beta-2
PE20040950A1 (es)	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US7345060B2 (en)	2003-11-21	2008-03-18	Theravance, Inc.	Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
ES2289691T3 (es)	2004-01-22	2008-02-01	Pfizer, Inc.	Derivados de sulfonamida para el tratamiento de enfermedades.
WO2005092861A1 (en)	2004-03-11	2005-10-06	Pfizer Limited	Quinolinone derivatives pharmaceutical compositions containing them and their use
US7538141B2 (en)	2004-03-23	2009-05-26	Alan Daniel Brown	Compounds for the treatment of diseases
WO2005092840A1 (en)	2004-03-23	2005-10-06	Pfizer Limited	Formamide derivatives useful as adrenoceptor
ES2257152B1 (es) *	2004-05-31	2007-07-01	Laboratorios Almirall S.A.	Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1778626A1 (en)	2004-08-16	2007-05-02	Theravance, Inc.	Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP1833822A2 (en)	2004-08-16	2007-09-19	Theravance, Inc.	Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
FR2898640B1 (fr)	2006-03-20	2008-04-25	Siemens Vdo Automotive Sas	Procede de transmission d'information relatif au fonctionnement d'un moteur a combustion interne
EP2080523A1 (en) *	2008-01-15	2009-07-22	CHIESI FARMACEUTICI S.p.A.	Compositions comprising an antimuscarinic and a long-acting beta-agonist
WO2010123766A1 (en)	2009-04-23	2010-10-28	Theravance, Inc.	DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
US9072734B2 (en) *	2009-04-30	2015-07-07	Teijin Pharma Limited	Quaternary ammonium salt compounds
WO2011048409A1 (en)	2009-10-20	2011-04-28	Astrazeneca Ab	Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP2718281B1 (en)	2011-06-10	2015-09-09	Chiesi Farmaceutici S.p.A.	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
HRP20151317T1 (hr) *	2011-06-10	2016-01-01	Chiesi Farmaceutici S.P.A.	Spojevi koji pokazuju aktivnost prema antagonistima muskarinskog receptora i beta2 adrenergiäśnog receptora
MX369311B (es) *	2012-12-06	2019-11-05	Chiesi Farm Spa	Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico.
RU2661877C2 (ru) *	2012-12-06	2018-07-20	КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.	Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов

2013
- 2013-12-05 MX MX2015006788A patent/MX369311B/es active IP Right Grant
- 2013-12-05 AU AU2013354043A patent/AU2013354043C1/en not_active Ceased
- 2013-12-05 SI SI201331764T patent/SI3345904T1/sl unknown
- 2013-12-05 SI SI201330994T patent/SI2928889T1/en unknown
- 2013-12-05 HU HUE18156043A patent/HUE051394T2/hu unknown
- 2013-12-05 GE GEAP201313845A patent/GEP20186839B/en unknown
- 2013-12-05 PT PT181560434T patent/PT3345904T/pt unknown
- 2013-12-05 CN CN201380063365.2A patent/CN104822678B/zh not_active Expired - Fee Related
- 2013-12-05 NZ NZ708738A patent/NZ708738A/en not_active IP Right Cessation
- 2013-12-05 EP EP18156043.4A patent/EP3345904B1/en active Active
- 2013-12-05 MA MA38147A patent/MA38147B1/fr unknown
- 2013-12-05 PT PT138118278T patent/PT2928889T/pt unknown
- 2013-12-05 HR HRP20180915TT patent/HRP20180915T1/hr unknown
- 2013-12-05 JP JP2015546012A patent/JP6421989B2/ja not_active Expired - Fee Related
- 2013-12-05 EA EA201590873A patent/EA030552B1/ru unknown
- 2013-12-05 UA UAA201505478A patent/UA118181C2/uk unknown
- 2013-12-05 PL PL13811827T patent/PL2928889T3/pl unknown
- 2013-12-05 DK DK13811827.8T patent/DK2928889T3/en active
- 2013-12-05 BR BR112015012730-4A patent/BR112015012730B1/pt not_active IP Right Cessation
- 2013-12-05 DK DK18156043.4T patent/DK3345904T3/da active
- 2013-12-05 PE PE2015000738A patent/PE20151216A1/es active IP Right Grant
- 2013-12-05 PL PL18156043T patent/PL3345904T3/pl unknown
- 2013-12-05 TW TW102144561A patent/TWI637954B/zh not_active IP Right Cessation
- 2013-12-05 LT LTEP18156043.4T patent/LT3345904T/lt unknown
- 2013-12-05 KR KR1020157014956A patent/KR102156443B1/ko not_active Expired - Fee Related
- 2013-12-05 LT LTEP13811827.8T patent/LT2928889T/lt unknown
- 2013-12-05 AR ARP130104529A patent/AR093825A1/es unknown
- 2013-12-05 TR TR2018/08698T patent/TR201808698T4/tr unknown
- 2013-12-05 KR KR1020207006181A patent/KR102240459B1/ko active Active
- 2013-12-05 EP EP13811827.8A patent/EP2928889B1/en active Active
- 2013-12-05 SG SG11201504318UA patent/SG11201504318UA/en unknown
- 2013-12-05 RS RS20201150A patent/RS60864B1/sr unknown
- 2013-12-05 HU HUE13811827A patent/HUE037944T2/hu unknown
- 2013-12-05 ES ES13811827.8T patent/ES2670686T3/es active Active
- 2013-12-05 SG SG10201704032RA patent/SG10201704032RA/en unknown
- 2013-12-05 ES ES18156043T patent/ES2816210T3/es active Active
- 2013-12-05 WO PCT/EP2013/075661 patent/WO2014086924A1/en not_active Ceased
- 2013-12-05 RS RS20180529A patent/RS57232B1/sr unknown
- 2013-12-05 CA CA2893626A patent/CA2893626C/en active Active
- 2013-12-06 US US14/098,735 patent/US8987299B2/en active Active
2015
- 2015-01-23 US US14/603,926 patent/US9371318B2/en active Active
- 2015-06-02 CL CL2015001483A patent/CL2015001483A1/es unknown
- 2015-06-03 CO CO15127118A patent/CO7400870A2/es unknown
- 2015-06-03 IL IL239182A patent/IL239182B/en active IP Right Grant
- 2015-06-03 ZA ZA2015/03965A patent/ZA201503965B/en unknown
- 2015-06-03 PH PH12015501247A patent/PH12015501247B1/en unknown
- 2015-06-03 SA SA515360514A patent/SA515360514B1/ar unknown
- 2015-06-03 TN TNP2015000244A patent/TN2015000244A1/fr unknown
2018
- 2018-05-03 CY CY20181100469T patent/CY1120159T1/el unknown
2020
- 2020-09-09 HR HRP20201435TT patent/HRP20201435T1/hr unknown
- 2020-09-28 CY CY20201100912T patent/CY1123365T1/el unknown

Also Published As

Publication number	Publication date
US20150133491A1 (en)	2015-05-14
US20140161736A1 (en)	2014-06-12
PT2928889T (pt)	2018-05-29
KR102156443B1 (ko)	2020-09-17
LT3345904T (lt)	2020-09-25
TN2015000244A1 (en)	2016-10-03
CA2893626A1 (en)	2014-06-12
CN104822678A (zh)	2015-08-05
US9371318B2 (en)	2016-06-21
TW201427976A (zh)	2014-07-16
AU2013354043C1 (en)	2017-08-31
KR20200027049A (ko)	2020-03-11
HUE037944T2 (hu)	2018-09-28
CL2015001483A1 (es)	2015-10-23
PT3345904T (pt)	2020-09-07
IL239182A0 (en)	2015-07-30
CA2893626C (en)	2021-08-24
EP2928889A1 (en)	2015-10-14
CN104822678B (zh)	2017-03-08
AU2013354043B2 (en)	2017-06-15
BR112015012730A2 (pt)	2017-07-11
RS60864B1 (sr)	2020-11-30
AR093825A1 (es)	2015-06-24
PH12015501247B1 (en)	2019-02-06
EA201590873A1 (ru)	2015-09-30
IL239182B (en)	2018-12-31
SG11201504318UA (en)	2015-07-30
HK1212989A1 (zh)	2016-06-24
KR20150090108A (ko)	2015-08-05
CO7400870A2 (es)	2015-09-30
CY1123365T1 (el)	2021-12-31
TR201808698T4 (tr)	2018-07-23
BR112015012730B1 (pt)	2022-07-05
ZA201503965B (en)	2016-09-28
KR102240459B1 (ko)	2021-04-16
EA030552B1 (ru)	2018-08-31
EP2928889B1 (en)	2018-03-21
MX2015006788A (es)	2015-08-05
EP3345904A1 (en)	2018-07-11
MA38147B1 (fr)	2018-09-28
PL2928889T3 (pl)	2018-09-28
SI2928889T1 (en)	2018-05-31
WO2014086924A1 (en)	2014-06-12
RS57232B1 (sr)	2018-07-31
ES2670686T3 (es)	2018-05-31
TWI637954B (zh)	2018-10-11
SG10201704032RA (en)	2017-06-29
SI3345904T1 (sl)	2020-09-30
MX369311B (es)	2019-11-05
ES2816210T3 (es)	2021-03-31
JP2016502557A (ja)	2016-01-28
US8987299B2 (en)	2015-03-24
JP6421989B2 (ja)	2018-11-14
UA118181C2 (uk)	2018-12-10
MA38147A1 (fr)	2018-03-30
CY1120159T1 (el)	2018-12-12
DK2928889T3 (en)	2018-05-22
HRP20201435T1 (hr)	2020-11-27
GEP20186839B (en)	2018-04-10
EP3345904B1 (en)	2020-07-29
DK3345904T3 (da)	2020-08-31
PH12015501247A1 (en)	2015-08-17
SA515360514B1 (ar)	2016-08-30
LT2928889T (lt)	2018-06-11
HRP20180915T1 (hr)	2018-07-27
HUE051394T2 (hu)	2021-03-01
NZ708738A (en)	2019-02-22
PE20151216A1 (es)	2015-09-08

Publication	Publication Date	Title
PL2928890T3 (pl)	2018-07-31	Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych
ZA201503965B (en)	2016-09-28	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
ZA201309242B (en)	2015-05-27	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
KR20180085068A (ko)	2018-07-25	무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물
IL215554A0 (en)	2011-12-29	Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
SI2776425T1 (sl)	2016-10-28	Novi derivati cikloheksilamina, ki delujejo kot zaviralci andregeneričnih receptorjev beta2 in zaviralci muskarinskih receptorjev m3
PL2569308T3 (pl)	2017-05-31	Nowe pochodne cykloheksyloaminowe o aktywności agonisty receptora b2-adrenergicznego i antagonisty receptora muskarynowego m3
IL253922B (en)	2019-11-28	Compounds with muscarinic receptor antagonist and adrenergic receptor agonist activity in cell 2
IL236702A0 (en)	2015-02-26	5–ht3 receptor antagonists
IL239118A0 (en)	2015-07-30	New cyclohexyl and quinoclidinyl carbamate compounds with beta-2 adrenergic agonistic and m3 muscarinic antagonistic activity